CN114732150A - 具有安神助眠功效的电子烟烟液 - Google Patents
具有安神助眠功效的电子烟烟液 Download PDFInfo
- Publication number
- CN114732150A CN114732150A CN202210365424.2A CN202210365424A CN114732150A CN 114732150 A CN114732150 A CN 114732150A CN 202210365424 A CN202210365424 A CN 202210365424A CN 114732150 A CN114732150 A CN 114732150A
- Authority
- CN
- China
- Prior art keywords
- parts
- essential oil
- effects
- electronic cigarette
- sleep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003571 electronic cigarette Substances 0.000 title claims abstract description 29
- 230000000694 effects Effects 0.000 title claims abstract description 24
- 210000005036 nerve Anatomy 0.000 title claims abstract description 18
- 241000208125 Nicotiana Species 0.000 title abstract description 5
- 235000002637 Nicotiana tabacum Nutrition 0.000 title abstract description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 title description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 57
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 45
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 43
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000000341 volatile oil Substances 0.000 claims abstract description 32
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 30
- 239000007788 liquid Substances 0.000 claims abstract description 24
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 19
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 19
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960003987 melatonin Drugs 0.000 claims abstract description 19
- 229940026510 theanine Drugs 0.000 claims abstract description 15
- 235000013311 vegetables Nutrition 0.000 claims abstract description 15
- 241000196324 Embryophyta Species 0.000 claims abstract description 14
- 241000207840 Jasminum Species 0.000 claims description 5
- 235000010254 Jasminum officinale Nutrition 0.000 claims description 5
- 241000220317 Rosa Species 0.000 claims description 5
- 240000000513 Santalum album Species 0.000 claims description 5
- 235000008632 Santalum album Nutrition 0.000 claims description 5
- 235000019504 cigarettes Nutrition 0.000 claims description 5
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 3
- 240000002319 Citrus sinensis Species 0.000 claims description 3
- 230000002936 tranquilizing effect Effects 0.000 abstract description 2
- 230000000391 smoking effect Effects 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 239000002994 raw material Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 6
- 238000000889 atomisation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004620 sleep latency Effects 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical class CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000796 barbital sodium Drugs 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供具有安神助眠功效的电子烟烟液,包含:1‑5份褪黑素,1‑2份茶氨酸,1‑2份γ-氨基丁酸,1‑2份的柠檬酸,1‑10份的天然植物精油,2‑40份丙二醇,40‑60份蔬菜甘油。该烟油具有安神助眠的功效,同时又可以满足抽烟人士抽烟感。
Description
技术领域
本发明涉及电子烟技术领域,具体涉及一种具有安神助眠功效的电子烟烟液。
背景技术
电子烟是通过雾化器将液体变成蒸汽,雾化产生烟雾。传统电子烟仍主要以尼古丁盐作为添加物,依然会有产生成瘾性等问题。
目前,虽然也有一些电子烟烟油采用中药提取物,但是由于电子烟的雾化温度低,采用常规具有安神助眠效果的中药提取物根本无法达到升华点,导致常规中药提取物添加成分的雾化效率低,无法有效达到所追求的安神助眠功效。
发明内容
基于此,有必要提供一种具有安神助眠功效的电子烟烟液及其制备方法。
本发明采用如下技术方案:
本发明一种具有安神助眠功效的电子烟烟液,主要由如下体积份的组分制备而成:1-5份褪黑素,0.5-2份茶氨酸,0.5-2份γ-氨基丁酸,,1-10份的天然植物精油,2-40份丙二醇,40-65份蔬菜甘油。
在其中一些实施例中,所述具有安神助眠功效的电子烟烟液主要由如下体积份的组分制备而成:1-3份褪黑素,0.5-1.5份茶氨酸,0.5-1.5份γ-氨基丁酸,0.5-1.5份的柠檬酸,1-6份的天然植物精油,25-40份丙二醇,55-65份蔬菜甘油。
在其中一些实施例中,所述具有安神助眠功效的电子烟烟液主要由如下体积份的组分制备而成:2份褪黑素,1份茶氨酸,1份γ-氨基丁酸,1份的柠檬酸,1-6份的天然植物精油,27~36份丙二醇,60份蔬菜甘油。
在其中一些实施例中,天然植物精油选自天然茉莉精油、天然甜橙精油、天然玫瑰精油或檀香精油中至少一种。
在其中一些实施例中,所述天然植物精油更有选自天然茉莉精油、天然玫瑰精油或檀香精油中至少一种。
在其中一些实施例中,所述具有安神助眠功效的电子烟烟液还包括柠檬酸,柠檬酸与褪黑素、γ-氨基丁酸的体积比为(0.5-2):(0.5-2):(0.5-2)。
在其中一些实施例中,更优选地,柠檬酸与褪黑素、γ-氨基丁酸的体积比为1:2:1。
本发明的有益效果是:
与现有技术相比,本发明具有安神助眠功效的电子烟烟液采用特定配比的褪黑素、茶氨酸、γ-氨基丁酸、柠檬酸、天然植物精油、丙二醇、蔬菜甘油复配,整体上能够达到安神助眠的功效,同时可以进一步防止储存过程发生褐变。
附图说明
图1为实施例1与对比例1的样品褐变情况对比图。
具体实施方式
下面结合具体实施例对本发明作进一步的详细说明,以使本领域的技术人员更加清楚地理解本发明。
以下各实施例,仅用于说明本发明,但不止用来限制本发明的范围。基于本发明中的具体实施例,本领域普通技术人员在没有做出创造性劳动的情况下,所获得的其他所有实施例,都属于本发明的保护范围。
在本发明实施例中,若无特殊说明,所有原料组分均为本领域技术人员熟知的市售产品;在本发明实施例中,若未具体指明,所用的技术手段均为本领域技术人员所熟知的常规手段。
实施例1
本实施例提供一种电子烟烟液,由如下体积份的原料混合制备而成:2份褪黑素,1份茶氨酸,1份γ-氨基丁酸,1份柠檬酸,35份丙二醇,60份蔬菜甘油。
实施例2
本实施例提供一种电子烟烟液,由如下体积份的原料混合制备而成:2份褪黑素,1份茶氨酸,1份γ-氨基丁酸,1份柠檬酸,5份天然茉莉精油,30份丙二醇,60份蔬菜甘油。
实施例3
本实施例提供一种电子烟烟液,由如下体积份的原料混合制备而成:2份褪黑素,1份茶氨酸,1份γ-氨基丁酸,1份柠檬酸,5份天然甜橙精油,27份丙二醇,60份蔬菜甘油。
实施例4
本实施例提供一种电子烟烟液,由如下体积份的原料混合制备而成:2份褪黑素,1份茶氨酸,1份γ-氨基丁酸,1份柠檬酸,3份天然玫瑰精油,32份丙二醇,60份蔬菜甘油。
实施例5
本实施例提供一种电子烟烟液,由如下体积份的原料混合制备而成:2份褪黑素,1份茶氨酸,1份γ-氨基丁酸,1份柠檬酸,1份天然檀香精油,34份丙二醇,60份蔬菜甘油。
对比例1
本对比例提供一种电子烟烟液,由如下体积份的原料混合制备而成:2份褪黑素,1份茶氨酸,1份γ-氨基丁酸,36份丙二醇,60份蔬菜甘油。
分别对实施例以及对比例的组分进行汇总统计,如下表所示:
各试验例的组分用量表(体积份)
分别采用戊巴比妥钠阈下剂量催眠实验和巴比妥钠睡眠潜伏期实验炎症实施例中所述烟油的安神助眠作用。具体方法步骤如下:
取C57小鼠,分为空白对照组、实施例1-5组和对比例1组,每组8只小鼠。采用电子加热雾化器,雾化处理30分钟后,各组小鼠腹腔注射经预实验确定剂量为24mg/kg的戊巴比妥钠溶液,以翻正反射消失1min以上作为入睡指标,记录各组小鼠入睡只数及入睡时间。采用电子加热雾化器,170度雾化处理30分钟,后,各组小鼠腹腔注射经预实验确定剂量为230mg/kg的巴比妥钠,注射量为0.2mL/20g。以翻正反射消失1min以上作为入睡指标,根据小鼠的入睡情况,计算睡眠发生率(入睡小鼠个数/总个数)记录各组小鼠的睡眠潜伏期。
试验统计结果见下表:
试验例 | 睡眠发生率(%) | 睡眠潜伏期(S) |
空白对照组 | 12.5% | 2386.2 |
实施例1 | 37.5% | 1751.5 |
实施例2 | 50% | 1628.1 |
实施例3 | 37.5% | 1693.2 |
实施例4 | 50% | 1605.3 |
实施例5 | 50% | 1572.9 |
对比例1 | 37.5% | 1715.6 |
与空白对照组相比,实施例组和对比例组能显著提高小鼠的睡眠发生率和缩短小鼠进入睡眠的时间,所优选的植物精油表现出了显著的协同效应。柠檬酸的加入对所优选配方的助睡眠的功效无影响。
分别取实施例1和对比例1的电子烟烟液1mL置于室温下放置1周,观察颜色变化。1周的变化如图1所示,与对比例1相比,实施例1的样品并没有发生褐变反应,产品的稳定性更好。
另外,值得说明的是,本发明通过大量试验筛选获得由特定配比(1-5份褪黑素,0.5-2份茶氨酸,0.5-2份γ-氨基丁酸,1-10份的天然植物精油,2-40份丙二醇,40-65份蔬菜甘油)的组分制备而成电子烟烟液,整体才能够在较低雾化温度条件下达到安神助眠的功效。
在此有必要指出的是,以上实施例仅限于对本发明的技术方案做进一步的阐述和说明,并不是对本发明的技术方案的进一步的限制,本发明的方法仅为较佳的实施方案,并非用于限定本发明的保护范围。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (7)
1.一种具有安神助眠功效的电子烟烟液,其特征在于,主要由如下体积份的组分制备而成:1-5份褪黑素,0.5-2份茶氨酸,0.5-1.5份的柠檬酸,0.5-2份γ-氨基丁酸,1-10份的天然植物精油,2-40份丙二醇,40-65份蔬菜甘油。
2.根据权利要求1所述的具有安神助眠功效的电子烟烟液,其特征在于,主要由如下体积份的组分制备而成:1-3份褪黑素,0.5-1.5份茶氨酸,0.5-1.5份γ-氨基丁酸,0.5-1.5份的柠檬酸,1-6份的天然植物精油,25-40份丙二醇,55-65份蔬菜甘油。
3.根据权利要求2所述的具有安神助眠功效的电子烟烟液,其特征在于,其特征在于,主要由如下体积份的组分制备而成:2份褪黑素,1份茶氨酸,1份γ-氨基丁酸,1份的柠檬酸,1-6份的天然植物精油,27~36份丙二醇,60份蔬菜甘油。
4.根据权利要求1至3任一项所述的具有安神助眠功效的电子烟烟液,其特征在于,所述天然植物精油选自天然茉莉精油、天然甜橙精油、天然玫瑰精油或檀香精油中至少一种。
5.根据权利要求4所述的具有安神助眠功效的电子烟烟液,其特征在于,所述天然植物精油选自天然茉莉精油、天然玫瑰精油或檀香精油中至少一种。
6.根据权利要求1至3任一项所述的具有安神助眠功效的电子烟烟液,其特征在于,还包括柠檬酸,柠檬酸与褪黑素、γ-氨基丁酸的体积比为(0.5-2):(0.5-2):(0.5-2)。
7.根据权利要求6所述的具有安神助眠功效的电子烟烟液,其特征在于,柠檬酸与褪黑素、γ-氨基丁酸的体积比为1:2:1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210365424.2A CN114732150A (zh) | 2022-04-07 | 2022-04-07 | 具有安神助眠功效的电子烟烟液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210365424.2A CN114732150A (zh) | 2022-04-07 | 2022-04-07 | 具有安神助眠功效的电子烟烟液 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114732150A true CN114732150A (zh) | 2022-07-12 |
Family
ID=82278557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210365424.2A Pending CN114732150A (zh) | 2022-04-07 | 2022-04-07 | 具有安神助眠功效的电子烟烟液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114732150A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104026731A (zh) * | 2014-07-01 | 2014-09-10 | 安徽中烟工业有限责任公司 | 一种养心安神功能型电子烟烟液 |
CN107233412A (zh) * | 2017-05-27 | 2017-10-10 | 江西中医药大学 | 一种促进睡眠的复方精油组合物及其制备方法和用途 |
CN108420121A (zh) * | 2018-05-29 | 2018-08-21 | 云南养瑞科技集团有限公司 | 一种具有改善睡眠功效的电子烟烟液及其制备方法 |
CN110179158A (zh) * | 2019-04-26 | 2019-08-30 | 薪火高科(深圳)有限公司 | 一种含蜂王酸和γ-氨基丁酸的电子烟烟液及其制备方法 |
CN111973672A (zh) * | 2020-09-11 | 2020-11-24 | 杜浩 | 一种助眠组合物及其制备方法 |
CN111991256A (zh) * | 2020-09-04 | 2020-11-27 | 广东丸美生物技术股份有限公司 | 一种具有安神助眠功效的护肤基质及其制备方法和应用 |
WO2021046919A1 (zh) * | 2019-09-12 | 2021-03-18 | 深圳雾芯科技有限公司 | 电子烟液 |
-
2022
- 2022-04-07 CN CN202210365424.2A patent/CN114732150A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104026731A (zh) * | 2014-07-01 | 2014-09-10 | 安徽中烟工业有限责任公司 | 一种养心安神功能型电子烟烟液 |
CN107233412A (zh) * | 2017-05-27 | 2017-10-10 | 江西中医药大学 | 一种促进睡眠的复方精油组合物及其制备方法和用途 |
CN108420121A (zh) * | 2018-05-29 | 2018-08-21 | 云南养瑞科技集团有限公司 | 一种具有改善睡眠功效的电子烟烟液及其制备方法 |
CN110179158A (zh) * | 2019-04-26 | 2019-08-30 | 薪火高科(深圳)有限公司 | 一种含蜂王酸和γ-氨基丁酸的电子烟烟液及其制备方法 |
WO2021046919A1 (zh) * | 2019-09-12 | 2021-03-18 | 深圳雾芯科技有限公司 | 电子烟液 |
CN111991256A (zh) * | 2020-09-04 | 2020-11-27 | 广东丸美生物技术股份有限公司 | 一种具有安神助眠功效的护肤基质及其制备方法和应用 |
CN111973672A (zh) * | 2020-09-11 | 2020-11-24 | 杜浩 | 一种助眠组合物及其制备方法 |
Non-Patent Citations (3)
Title |
---|
朱东来等: "《电子烟》", 31 August 2015, 云南大学出版社 * |
李建颖: "《食品添加剂速查手册》", 30 November 2017, 南开大学出版社 * |
熊瑛等: "《女人代谢好,肌肤更年轻》", 30 November 2016, 黑龙江科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2587508A (en) | Method for preparing low-suction-resistance polylactic acid tow filter rod used for reducing temperature of cigarette vapor | |
US20160366928A1 (en) | Solvent for electronic cigarette liquid and an electronic cigarette liquid | |
CN111406970B (zh) | 一种烟用焦甜香基 | |
US20160366927A1 (en) | A solvent for electronic cigarette liquid and an electronic cigarette liquid | |
CN106136311A (zh) | 一种非烟草新型卷烟及其制备方法 | |
CN105154234A (zh) | 一种烟用增香用调配香精及其制备方法 | |
CN104397871A (zh) | 一种含茶叶提取物的电子烟烟油及其制备方法 | |
CN104287094A (zh) | 一种电子烟烟油溶剂及电子烟烟液 | |
CN110464043B (zh) | 用于加热不燃烧卷烟的清香香精及烟草薄片和不燃烧卷烟 | |
US2766146A (en) | Tobacco | |
CN113046180B (zh) | 一种电子烟用红枣味香精添加剂及其制备方法 | |
CN114732150A (zh) | 具有安神助眠功效的电子烟烟液 | |
KR20010001582A (ko) | 한약재를 이용한 금연제 제조방법 | |
CN1360857A (zh) | 基于燃烧调香技术的仿生液体烟叶制备方法 | |
CN111466608A (zh) | 一种液态海盐尼古丁及其制备方法 | |
US3890981A (en) | Novel process for altering the organoleptic properties of tobacco using one or more alpha-pyrones and process | |
CN110754684A (zh) | 含咖啡因的发烟颗粒及其制备方法与低温加热不燃烧制品 | |
CN114601192A (zh) | 一种止咳烟油及其制备方法 | |
US3861403A (en) | Novel tobacco product comprising one or more alpha-pyrones | |
CN112293787A (zh) | 一种用于加热不燃烧制品的雾化发烟材料 | |
CN111728261A (zh) | 一种具有覆盆子香韵风格特征的添加剂及其制备方法和包含其的卷烟 | |
CN104997156A (zh) | 一种茶香烟及其制备方法 | |
CN108576910B (zh) | 一种用于加热方式发烟凝胶滤棒及其制备方法 | |
CN104585869A (zh) | 一种含糖苷的电子烟烟液 | |
CN109744570A (zh) | 一种由茶叶制备香烟滤嘴添加剂的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220712 |